| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Trimetozine's mechanism of action, as a mild sedative, is thought to involve the central nervous system, likely through modulation of neurotransmitter systems. Its exact molecular target is not clearly defined in the available literature. It is a sedative and hypnotic agent. Its effects are mild and it has been utilized in anxiety research.
|
|---|---|
| ln Vitro |
In vitro, Trimetozine's activity is related to its sedative properties. It is not known to be a potent inhibitor of specific enzymes or receptors. Its biological effects are likely mediated through its interaction with the central nervous system. Specific in vitro data are not extensively detailed in the available literature.
|
| ln Vivo |
In vivo, Trimetozine is an orally active sedative agent. It has a mild tranquilizing effect and can be used in anxiety research. It is a member of the morpholine class of compounds.
|
| Enzyme Assay |
In vitro receptor binding or enzyme assays for Trimetozine are not standard, as its mechanism of action is not well-defined. Its activity might be assessed in a functional assay measuring neuronal activity, such as measuring the inhibition of spontaneous neuronal firing in cultured neurons.
|
| Cell Assay |
In vitro cell-based assays for Trimetozine are not commonly reported. If conducted, they might involve treating neuronal cell lines with the compound and measuring changes in intracellular calcium levels or neuronal network activity.
|
| Animal Protocol |
In vivo animal studies for Trimetozine would typically involve rodent models of anxiety, such as the elevated plus maze or the open field test. The compound is administered orally, and its effects on exploratory behavior and anxiety-like behaviors are measured.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of Trimetozine, such as half-life and bioavailability, are not detailed in the available literature. It is described as being orally active. It is a small molecule with a molecular weight of 281.30.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for Trimetozine are not provided in the available text. As a research compound, it is intended for laboratory use only and is not for human therapeutic use. Safety precautions should be followed.
|
| References | |
| Additional Infomation |
4-Morphyrin-(3,4,5-trimethoxyphenyl) methyl ketone is a member of the morpholine family of compounds.
Trimetozine is an orally active sedative with mild tranquilizing effects. It has been used in anxiety research. This product is for research use only. |
| Molecular Formula |
C14H19NO5
|
|---|---|
| Molecular Weight |
281.31
|
| Exact Mass |
281.126
|
| CAS # |
635-41-6
|
| PubChem CID |
12478
|
| Appearance |
White to off-white solid
|
| Density |
1.184g/cm3
|
| Boiling Point |
461.5ºC at 760 mmHg
|
| Melting Point |
120-122°
|
| Flash Point |
232.9ºC
|
| Index of Refraction |
1.529
|
| LogP |
1.122
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C(=CC(=C1)C(=O)N2CCOCC2)OC)OC
|
| InChi Key |
XWVOEFLBOSSYGM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H19NO5/c1-17-11-8-10(9-12(18-2)13(11)19-3)14(16)15-4-6-20-7-5-15/h8-9H,4-7H2,1-3H3
|
| Chemical Name |
morpholin-4-yl-(3,4,5-trimethoxyphenyl)methanone
|
| Synonyms |
Trimetozine Trioxyfar Opalene Sedoxazine NSC-62939 Trioxazin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~355.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (8.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5548 mL | 17.7740 mL | 35.5480 mL | |
| 5 mM | 0.7110 mL | 3.5548 mL | 7.1096 mL | |
| 10 mM | 0.3555 mL | 1.7774 mL | 3.5548 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
